MedTrace Logo

Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial

NCT05408546 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2023-07-11

No results posted yet for this study

Summary

Phase II trial of TS23

Conditions

Interventions

DRUG

TS23

Monoclonal antibody to a2-antiplasmin

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Translational Sciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Guy L Reed, MD · Translational Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-24
Primary Completion
2024-07-31
Completion
2024-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05408546 on ClinicalTrials.gov